Lotrich and Pollock Devlin B, Roeder K, Bacanu S-A. 2001. Unbiased methods for population- based association studies. Genet Epidemiol, 21:273–84. Devlin B, Roeder K, Wasserman L. 2003. Analysis of multilocus models of association. Genet Epidemiol, 25:36–47. Dhaenen H. 2001. Imaging the serotonergic system in depression. Eur Arch Psychiatry Clin Neurosci, 251:1176–80. Di Blasio AM, van Rossum EF, Maestrini S, et al. 2003. The relation between two polymorphisms in the glucocorticoid receptor gene and body mass index, blood pressure and cholesterol in obese patients. Clin Endocrinol, 59:68–74. Dowlatshahi D, MacQueen GM, Wang JF, et al. 1998. Increased temporal cortex CREB concentrations and antidepressant treatment in major depression. Lancet, 352:1754–5. Downes GB, Gautam N. 1999. The G protein subunit gene families. Genomics, 62:544–52. Drevets WC. 1998. Functional neuroimaging studies of depression: the anatomy of melancholia. Annu Rev Med, 49:341–61. Du L, Bakish D, Lapierre YD, et al. 2000. Association of polymorphism of serotonin 2A receptor gene with suicidal ideation in major depressive disorder. Am J Med Genet, 96:56–60. Du L, Faludi G, Palkovits M, et al. 2001. Serotonergic genes and suicidality. Crisis J Crisis Interv Suicide, 22:54–60. Duman RS, Heninger GR, Nestler EJ. 1997. A molecular and cellular theory of depression. Arch Gen Psychiatry, 54:597–606. Duman RS, Malberg JE, Thome J. 1999. Neural plasticity to stress and antidepressant treatment. Biol Psychiatry, 46:1181–91. Dwivedi Y, Agrawal A, Rizavi H, et al. 2002. Antidepressants reduce phosphoinositide-specific phospholipase C (PI-PLC) activity and the mRNA and protein expression of selective PLC beta 1 isozyme in rat brain. Neuropharmacology, 43:1269–79. Dwivedi Y, Rizavi H, Roberts RC, et al. 2001. Reduced activation and expression of ERK1/2 MAP kinase in the post-mortem brain of depressed suicide subjects. J Neurochem, 77:916–28. Enoch MA, Goldman D, Barnett R, et al. 1999. Association between seasonal affective disorder and the 5-HT2A promoter polymorphism, -1438G/A. Mol Psychiatry, 4:89–92. Evans WE, McLeod HL. 2003. Pharmacogenomics – drug disposition, drug targets, and side effects. N Engl J Med, 348:538–49. Fairchild G, Leitch MM, Ingram CD. 2003. Acute and chronic effects of corticosterone on 5-HT1A receptor-mediated autoinhibition in the rat dorsal raphe nucleus. Neuropharmacology, 45:925–34. Fehr C, Shirley RL, Belknap JK, et al. 2002. Congenic mapping of alcohol and pentobarbital withdrawal liability loci to a <1 centimorgan interval of murine chromosome 4: identification of Mpdz as a candidate gene. J Neurosci, 22:3730–8. Feng P, Guan Z, Yang X, et al. 2003. Impairments of ERK signal transduction in the brain in a rat model of depression induced by neonatal exposure of clomipramine. Brain Res, 991:195–205. Galeotti N, Bartolini A, Ghelardini C. 2002. Role of Gi proteins in the antidepressant-like effect of amitriptyline and clomipramine. Neuropsychopharmacology, 27:554–64. Galter D, Unsicker K. 2000. Brain-derived neurotrophic factor and trkB are essential for cAMP-mediated induction of the serotonergic neuronal phenotype. J Neurosci Res, 61:295–301. Gill CH, Soffin EM, Hagan JJ, et al. 2002. 5-HT7 receptors modulate synchronized network activity in rat hippocampus. Neuropharmacology, 42:82–92. Gilmor ML, Owens MJ, Nemeroff CB. 2002. Inhibition of norepinephrine uptake in patients with major depression treated with paroxetine. Am J Psychiatry, 159:1702–10. Gloyn AL, Desa IM, Clark A, et al. 2002. Human calcium/calmodulin- dependent protein kinase II gamma gene (CAMK2G): cloning, genomic structure and detection of variants in subjects with type II diabetes. Diabetologia, 45:580–3. Gold PW, Chrousos GP. 2002. Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs low CRH/NE states. Mol Psychiatry, 7:254–75. 30 Gold PW, Goodwin FK, Chrousos GP. 1988. Clinical and biochemical manifestations of depression: relation to the neurobiology of stress (1). N Engl J Med, 319:348–53. Gomez LL, Alam S, Smith KE, et al. 2002. Regulation of A-kinase anchoring protein 79/150-cAMP-dependent protein kinase postsynaptic targeting by NMDA receptor activation of calcineurin and remodeling of dendritic actin. J Neurosci, 22:7027–44. Gonzalez-Gay MA, Hajeer AH, Garcia-Porrua C, et al. 2003. Corticotropin- releasing hormone promoter polymorphisms in patients with rheumatoid arthritis from northwest Spain. J Rheumatol, 30:913–17. Gould TD, Manji HK. 2002. Signaling networks in the pathophysiology and treatment of mood disorders. J Psychosom Res, 53:687–97. Gurguis GN, Vo SP, Griffith JM, et al. 1999. Platelet alpha2A-adrenoceptor function in major depression: Gi coupling, effects of imipramine and relationship to treatment outcome. Psychiatry Res, 89:73–95. Hawi Z, Dring M, Kirley A, et al. 2002. Serotonergic system and attention deficit hyperactivity disorder (ADHD): a potential susceptibility locus at the 5-HT(1B) receptor gene in 273 nuclear families from a multi- centre sample. Mol Psychiatry, 7:718–25. Heils A, Mossner R, Lesch KP. 1997. The human serotonin transporter gene polymorphism – basic research and clinical implication. J Neural Transm, 104:1005–14. Hellevuo K, Welborn R, Menninger JA, et al. 1997. Human adenylyl cyclase type 7 contains polymorphic repeats in the 3´ untranslated region: investigations of association with alcoholism. Am J Med Genet, 74: 95–8. Helmeste DM, Tang SW. 1995. Tyrosine kinase inhibitors regulate serotonin uptake in platelets. Eur J Pharmacol, 280:R5–7. Herr AS, Tsolakidou AF, Yassouridis A, et al. 2003. Antidepressants differentially influence the transcriptional activity of the glucocorticoid receptor in vitro. Neuroendocrinology, 78:12–22. Hoehe MR, Timmermann B, Lehrach H. 2003. Human inter-individual DNA sequence variation in candidate genes, drug targets, the importance of haplotypes and pharmacogenomics. Curr Pharm Biotechnol, 4:351–78. Holmes C, Arranz M, Collier D, et al. 2003. Depression in Alzheimer’s disease: the effect of serotonin receptor gene variation. Am J Med Genet, 119B:40–3. Holsboer F. 2000. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology, 23:477–501. Hong CJ, Huo SJ, Yen FC, et al. 2003. Association study of a brain-derived neurotrophic-factor genetic polymorphism and mood disorders, age of onset and suicidal behavior. Neuropsychobiology, 48:186–9. Huizenga NATM, Koper JW, De Lange P, et al. 1998. A polymorphism in the glucocorticoid receptor gene may be associated with an increased sensitivity to glucocorticoids in vivo. J Clin Endocrinol Metab, 83: 144–51. Ito K, Yoshida K, Sato K, et al. 2002. A variable number of tandem repeats in the serotonin transporter gene does not affect the antidepressant response to fluvoxamine. Psychiatry Res, 111:235–9. Iversen L. 2000. Neurotransmitter transporters: fruitful targets for CNS drug discovery. Mol Psychiatry, 5:357–62. Jensen JB, Mikkelsen JD, Mork A. 2000. Increased adenylyl cyclase type 1 mRNA, but not adenylyl cyclase type 2 in the rat hippocampus following antidepressant treatment. Eur Neuropsychopharmacol, 10:105–11. Jia H, Hingorani AD, Sharma P, et al. 1999. Association of the G(s)alpha gene with essential hypertension and response to beta-blockade. Hypertension, 34:8–14. Jonsson EG, Cichon S, Gustavsson JP, et al. 2003. Association between a promoter dopamine D2 receptor gene variant and the personality trait detachment. Biol Psychiatry, 53:577–84. Jonsson EG, Nothen MM, Gustavsson JP, et al. 1998. Polymorphisms in the dopamine, serotonin, and norepinephrine transporter genes and their relationships to monoamine metabolite concentrations in CSF of healthy volunteers. Psychiatry Res, 79:1–9. Neuropsychiatric Disease and Treatment 2005:1(1)